We're all set for a new experience. To visit the old Ventura website, click here.
Ventura Wealth Clients Login here

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open945.1
High945.5
Low934.05
Prev. Close940.4
Avg. Traded Price939.18
Volume5,571

MARKET DEPTH

info2
Total bid13,879.00
Total ask12,076.00
OrdersQtyBid
25941.05
216941
110940.8
25940.7
11940.65
AskQtyOrders
942.5213
942.8511
942.912
94312
943.214

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

934.052 hours ago
945.502 hours ago
arrow

LOWER/UPPER CIRCUITS

752.35
1,128.45
arrow
Tatva Chintan Pharma Chem Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral
noteQuarterly Revenue,rose 9.77% YoY to ₹108.59 Cr. Its sector's average revenue growth YoY for the quarter was 10.04%.
noteInterest Coverage Ratio,is 28.32, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).
noteDebt to Equity Ratio,of 0.05 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
View more

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : %
Net profit growth 5Y CAGR : %
Tatva Chintan Pharma Chem Limited is a specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC). The company is the largest and only commercial manufacturer of SDAs for zeolites in India. It also enjoys the second largest position globally. In addition, the company is one of the leading global producers of an entire range of PTCs in India and one of the key producers across the globe. As a manufacturer of specialty chemicals, it focuses on application of its products which form a key ingredient to its customers’ manufacturing and industrial processes.
personal

Grow your wealth with more research recommendations

+91